Paige Vinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paige Vinson has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Reece
Southern Research, Scientific Platforms Division, 2000 9th Ave South, Birmingham, AL 35205, USA
3 shared publications Anna Manuvakhova
Southern Research, Scientific Platforms Division, 2000 9th Ave South, Birmingham, AL 35205, USA
3 shared publicationsC. David Weaver
Department of Chemistry, Department of Pharmacology, and Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee
3 shared publications- Pedro Ruiz
Southern Research, Scientific Platforms Division, 2000 9th Ave South, Birmingham, AL 35205, USA
3 shared publications Sara McKellip
Southern Research, Scientific Platforms Division, 2000 9th Ave South, Birmingham, AL 35205, USA
3 shared publications- Yohanka Martinez-Gzegozewska
Southern Research, Scientific Platforms Division, 2000 9th Ave South, Birmingham, AL 35205, USA
3 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Elsevier in Molecular Pharmacology
- Vol. 108 (5-6) , 100130
Identification of potent and selective small molecule TALK-1 inhibitors that promote β-cell function
- 15 May 2026
- Published by Elsevier in Molecular Pharmacology
- Vol. 108 (5-6) , 100130
Open AccessIdentification of potent and selective small molecule TALK-1 inhibitors that promote β-cell function
- Open Access
- 6 June 2025
- Published by Elsevier in Antiviral Research
- Vol. 240, 106209
High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay
- 6 June 2025
- Published by Elsevier in Antiviral Research
- Vol. 240, 106209
Open AccessHigh-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay
- Open Access
- 16 May 2024
- Published by Elsevier in SLAS Discovery
- Vol. 29 (5) , 100160
A high-throughput response to the SARS-CoV-2 pandemic
- 16 May 2024
- Published by Elsevier in SLAS Discovery
- Vol. 29 (5) , 100160
Open AccessA high-throughput response to the SARS-CoV-2 pandemic
- Open Access
- 2 November 2023
- Published by Elsevier in SLAS Discovery
- Vol. 29 (1) , 66-76
High-Throughput cell-based immunofluorescence assays against influenza
- 2 November 2023
- Published by Elsevier in SLAS Discovery
- Vol. 29 (1) , 66-76
Open AccessHigh-Throughput cell-based immunofluorescence assays against influenza
- 16 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 15 (747) , eabq7618
A BRET Ca 2+ sensor enables high-throughput screening in the presence of background fluorescence
The intrinsic fluorescence of samples confounds the use of fluorescence-based sensors. This is of particular concern in high-throughput screening (HTS) applications using large chemical libraries containing intrinsically fluorescent compounds. To overcome this problem, we developed a bioluminescence resonance energy transfer (BRET) Ca 2+ sensor, CalfluxCTN. We demonstrated that it reliably reported changes in intracellular Ca 2+ concentrations evoked by an agonist and an antagonist of the human muscarinic acetylcholine receptor M 1 (hM 1 R) even in the presence of the fluorescent compound fluorescein, which interfered with a standard fluorescent HTS sensor (Fluo-8). In an HTS using a chemical library containing fluorescent compounds, CalfluxCTN accurately identified agonists and antagonists that were missed or miscategorized using Fluo-8. Moreover, we showed that a luciferase substrate that becomes activated only when inside cells generated long-lasting BRET signals in HTS, enabling results to be reliably compared among replicate samples for hours. Thus, the use of a self-luminescent sensor instead of a fluorescent sensor could facilitate the complete screening of chemical libraries in a high-throughput context and enable analysis of autofluorescent samples in many different applications.
- 16 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 15 (747) , eabq7618
A BRET Ca 2+ sensor enables high-throughput screening in the presence of background fluorescence
The intrinsic fluorescence of samples confounds the use of fluorescence-based sensors. This is of particular concern in high-throughput screening (HTS) applications using large chemical libraries containing intrinsically fluorescent compounds. To overcome this problem, we developed a bioluminescence resonance energy transfer (BRET) Ca 2+ sensor, CalfluxCTN. We demonstrated that it reliably reported changes in intracellular Ca 2+ concentrations evoked by an agonist and an antagonist of the human muscarinic acetylcholine receptor M 1 (hM 1 R) even in the presence of the fluorescent compound fluorescein, which interfered with a standard fluorescent HTS sensor (Fluo-8). In an HTS using a chemical library containing fluorescent compounds, CalfluxCTN accurately identified agonists and antagonists that were missed or miscategorized using Fluo-8. Moreover, we showed that a luciferase substrate that becomes activated only when inside cells generated long-lasting BRET signals in HTS, enabling results to be reliably compared among replicate samples for hours. Thus, the use of a self-luminescent sensor instead of a fluorescent sensor could facilitate the complete screening of chemical libraries in a high-throughput context and enable analysis of autofluorescent samples in many different applications.
- Open Access
- 29 July 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8400
Large-Scale Identification of Multiple Classes of Host Defense Peptide-Inducing Compounds for Antimicrobial Therapy
The rapid emergence of antibiotic resistance demands new antimicrobial strategies that are less likely to develop resistance. Augmenting the synthesis of endogenous host defense peptides (HDPs) has been proven to be an effective host-directed therapeutic approach. This study aimed to identify small-molecule compounds with a strong ability to induce endogenous HDP synthesis for further development as novel antimicrobial agents. By employing a stable HDP promoter-driven luciferase reporter cell line known as HTC/AvBD9-luc, we performed high-throughput screening of 5002 natural and synthetic compounds and identified 110 hits with a minimum Z-score of 2.0. Although they were structurally and functionally diverse, half of these hits were inhibitors of class I histone deacetylases, the phosphoinositide 3-kinase pathway, ion channels, and dopamine and serotonin receptors. Further validations revealed mocetinostat, a benzamide histone deacetylase inhibitor, to be highly potent in enhancing the expression of multiple HDP genes in chicken macrophage cell lines and jejunal explants. Importantly, mocetinostat was more efficient than entinostat and tucidinostat, two structural analogs, in promoting HDP gene expression and the antibacterial activity of chicken macrophages. Taken together, mocetinostat, with its ability to enhance HDP synthesis and the antibacterial activity of host cells, could be potentially developed as a novel antimicrobial for disease control and prevention.
- 29 July 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8400
Open AccessLarge-Scale Identification of Multiple Classes of Host Defense Peptide-Inducing Compounds for Antimicrobial Therapy
The rapid emergence of antibiotic resistance demands new antimicrobial strategies that are less likely to develop resistance. Augmenting the synthesis of endogenous host defense peptides (HDPs) has been proven to be an effective host-directed therapeutic approach. This study aimed to identify small-molecule compounds with a strong ability to induce endogenous HDP synthesis for further development as novel antimicrobial agents. By employing a stable HDP promoter-driven luciferase reporter cell line known as HTC/AvBD9-luc, we performed high-throughput screening of 5002 natural and synthetic compounds and identified 110 hits with a minimum Z-score of 2.0. Although they were structurally and functionally diverse, half of these hits were inhibitors of class I histone deacetylases, the phosphoinositide 3-kinase pathway, ion channels, and dopamine and serotonin receptors. Further validations revealed mocetinostat, a benzamide histone deacetylase inhibitor, to be highly potent in enhancing the expression of multiple HDP genes in chicken macrophage cell lines and jejunal explants. Importantly, mocetinostat was more efficient than entinostat and tucidinostat, two structural analogs, in promoting HDP gene expression and the antibacterial activity of chicken macrophages. Taken together, mocetinostat, with its ability to enhance HDP synthesis and the antibacterial activity of host cells, could be potentially developed as a novel antimicrobial for disease control and prevention.
- Open Access
- 1 May 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (21) , 7289-7300
Symmetrically substituted dichlorophenes inhibit N-acyl-phosphatidylethanolamine phospholipase D
- 1 May 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (21) , 7289-7300
Open AccessSymmetrically substituted dichlorophenes inhibit N-acyl-phosphatidylethanolamine phospholipase D
- Open Access
- 1 November 2012
- Published by Elsevier in Molecular Pharmacology
- Vol. 82 (5) , 860-875
Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships
Drug discovery programs increasingly are focusing on allosteric modulators as a means to modify the activity of G protein-coupled receptor (GPCR) targets. Allosteric binding sites are topographically distinct from the endogenous ligand (orthosteric) binding site, which allows for co-occupation of a single receptor with the endogenous ligand and an allosteric modulator that can alter receptor pharmacological characteristics. Negative allosteric modulators (NAMs) inhibit and positive allosteric modulators (PAMs) enhance the affinity and/or efficacy of orthosteric agonists. Established approaches for estimation of affinity and efficacy values for orthosteric ligands are not appropriate for allosteric modulators, and this presents challenges for fully understanding the actions of novel modulators of GPCRs. Metabotropic glutamate receptor 5 (mGlu5) is a family C GPCR for which a large array of allosteric modulators have been identified. We took advantage of the many tools for probing allosteric sites on mGlu5 to validate an operational model of allosterism that allows quantitative estimation of modulator affinity and cooperativity values. Affinity estimates derived from functional assays fit well with affinities measured in radioligand binding experiments for both PAMs and NAMs with diverse chemical scaffolds and varying degrees of cooperativity. We observed modulation bias for PAMs when we compared mGlu5-mediated Ca2+ mobilization and extracellular signal-regulated kinase 1/2 phosphorylation data. Furthermore, we used this model to quantify the effects of mutations that reduce binding or potentiation by PAMs. This model can be applied to PAM and NAM potency curves in combination with maximal fold-shift data to derive reliable estimates of modulator affinities.
- 1 November 2012
- Published by Elsevier in Molecular Pharmacology
- Vol. 82 (5) , 860-875
Open AccessInvestigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships
Drug discovery programs increasingly are focusing on allosteric modulators as a means to modify the activity of G protein-coupled receptor (GPCR) targets. Allosteric binding sites are topographically distinct from the endogenous ligand (orthosteric) binding site, which allows for co-occupation of a single receptor with the endogenous ligand and an allosteric modulator that can alter receptor pharmacological characteristics. Negative allosteric modulators (NAMs) inhibit and positive allosteric modulators (PAMs) enhance the affinity and/or efficacy of orthosteric agonists. Established approaches for estimation of affinity and efficacy values for orthosteric ligands are not appropriate for allosteric modulators, and this presents challenges for fully understanding the actions of novel modulators of GPCRs. Metabotropic glutamate receptor 5 (mGlu5) is a family C GPCR for which a large array of allosteric modulators have been identified. We took advantage of the many tools for probing allosteric sites on mGlu5 to validate an operational model of allosterism that allows quantitative estimation of modulator affinity and cooperativity values. Affinity estimates derived from functional assays fit well with affinities measured in radioligand binding experiments for both PAMs and NAMs with diverse chemical scaffolds and varying degrees of cooperativity. We observed modulation bias for PAMs when we compared mGlu5-mediated Ca2+ mobilization and extracellular signal-regulated kinase 1/2 phosphorylation data. Furthermore, we used this model to quantify the effects of mutations that reduce binding or potentiation by PAMs. This model can be applied to PAM and NAM potency curves in combination with maximal fold-shift data to derive reliable estimates of modulator affinities.